Advertisement
At this year's CyberKnife Users' meeting eight presentations reported onlarge scale studies, each with more than 100 patients with brain, lung orprostate tumors. Particular interest was expressed in prostate cancertreatment results, with multiple studies with two- and three-year follow-upthat demonstrated continued and sustained reduction in prostate specificantigen (PSA) levels, and no significant side effects in men treated forprostate cancer using CyberKnife radiosurgery during that period.
Advertisement
"We're pleased that so much progress has been made demonstrating positiveoutcomes using the CyberKnife System as a non-invasive treatment option forprostate cancer, including durable PSA level reductions up to three yearspost-treatment," said Michael Santoro, M.D., attending urologist at WinthropUniversity Hospital's CyberKnife Radiosurgery Center. "Patient satisfactionwith the procedure along with an excellent side effect profile is resulting inmore and more patient-to-patient referrals."
Additionally lung cancer treatment using the CyberKnife System continuedto draw a large amount of interest among the attendees with the presentationof experiences from clinicians around the world treating patients with lungtumors successfully with the CyberKnife System. This further validated thesignificant role CyberKnife treatment is playing in reshaping lung cancercare. In fact, during the meeting a majority of the institutions presentexpressed strong interest in the prospective clinical study that is being ledby M. D. Anderson Cancer Center in Houston comparing treatment outcomes withthe CyberKnife System versus surgery in early-stage, operable lung cancer.
Along with the enthusiasm around CyberKnife extracranial treatmentresults, the System remains a widely accepted tool in the treatment of braintumors. A data comparison of patients with acoustic tumors, treated by eitherCyberKnife or Gamma Knife radiosurgery demonstrated superior hearingpreservation in the patients treated with the CyberKnife System.
"This year's CyberKnife Users' meeting featured clinical data thatcontinue to support the growing usage of CyberKnife technology not only incancer care, but also the treatment of pain disorders and psychologicalillnesses," said Eric P. Lindquist, senior vice president and chief marketingofficer of Accuray Incorporated. "The meeting provided a forum for datasharing amongst some of the biggest leaders in the medical field, in an effortto provide the most safe, effective and comfortable care for patients."
Emerging CyberKnife treatment applications highlighted at the meetingdemonstrated promising results treating patients with breast cancer, bonecancer, kidney cancer and various pain syndromes. Centers continue to explorethese applications in the hopes of providing less invasive treatment optionsto their patients.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlledrobotic mobility, the CyberKnife System automatically tracks, detects andcorrects for tumor and patient movement in real-time throughout the treatment.This enables the CyberKnife System to deliver high-dose radiation withpinpoint precision, which minimizes damage to surrounding healthy tissue andeliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radio
